Skip to content
PEPLUX

Copper-binding tripeptide for injection

GHK-Cu Injection

Also called Copper tripeptide-1, Copper peptide GHK-Cu.

Illustrative PEPLUX product vial in a purple-lit studio
Product illustration

Product form

Subcutaneous injection

The process

Licensed provider review

GHK-Cu Injection cost

$229 per month

*If medically eligible.
Medication
Included
Clinician visit
Included
Baseline labs
Included
Lab retests
Included when ordered by your provider
Shipping
Included
Patient portal access
Included
Care-team chat support
Included

Considering more than one product?

  • Two products prescribed together: $349 per month
  • Three products prescribed together: $479 per month
Compare pricing

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

FDA status, checked on October 13, 2026

GHK-Cu Injection is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

Order now

No compounding pathway today.

*If medically eligible.

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

PEPLUX is a telehealth platform, not a pharmacy or drug manufacturer. Medications are compounded and dispensed by independently licensed US compounding pharmacies.

Prescription products require an online evaluation with a licensed provider. Not all patients qualify.

States served: not yet confirmed. How state availability works

What is GHK-Cu Injection?

GHK-Cu (copper tripeptide-1), supplied as a subcutaneous injection. This is a separate product from topical GHK-Cu.

Adults seeking a provider discussion about injected GHK-Cu after reviewing its limited human evidence and risks. The prescriber decides whether it is appropriate after an evaluation.

Key risks

  • The safety of injected GHK-Cu in people has not been established. Side effects, interactions and longer-term risks are not adequately characterized.
  • Injection can cause pain, redness, swelling or bruising, and carries an infection risk if the product or injection technique is not sterile.
All risks and who should not use it

FDA status

FDA status for GHK-Cu Injection.

Rendered from our regulatory records, which cite FDA, Federal Register and label documents directly. Each record shows the date we last checked it.

No compounding pathway today.

GHK-Cu Injection is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

GHK-Cu Injection

FDA interim enforcement discretion (Category 1). Not a listing. Not FDA-approved.

FDA’s documents list it as GHK-Cu.

GHK-Cu for non-injectable use, such as topical, is in FDA's 503A Category 1. FDA is still evaluating it and has said it does not intend to take action against a 503A pharmacy that compounds it against a patient-specific prescription while the interim policy's conditions are met. That is enforcement discretion, not a listing, and it has already been withdrawn once. Injectable GHK-Cu has no compounding pathway. Compounded GHK-Cu is not FDA-approved. FDA does not check the safety, effectiveness or quality of compounded drugs before they are sold.

FDA's Category 1 entry reads "GHK-Cu (except for injectable routes of administration)". It covers non-injectable routes, such as topical use, only. Subcutaneous, intramuscular and intravenous GHK-Cu are outside it.

Basis
FDA's 503A categories document (updated May 14, 2026) lists "GHK-Cu (except for injectable routes of administration)" in Category 1, bulk drug substances under evaluation. FDA removed GHK-Cu from Category 1 on April 22, 2026 after its nominations were withdrawn. On May 5, 2026 one nominator clarified that it meant to withdraw only the injectable route, and FDA added the non-injectable entry back. GHK-Cu is not in any 503B category and is not on the 503A bulks list in 21 CFR 216.23. Category 1 is FDA's interim enforcement discretion, not a statutory pathway.
Checked on
October 13, 2026

How it works

GHK-Cu Injection mechanism.

GHK-Cu is the tripeptide glycyl-histidyl-lysine bound to a copper ion. This listing concerns subcutaneous injection. The behavior of an injected formulation cannot be inferred from products applied to the skin.

That describes what the molecule does in the body. It is not a claim about what it will do for you.

What the evidence supports

GHK-Cu Injection: evidence and limitations.

Human data for injected GHK-Cu are minimal, and its safety and effectiveness by injection have not been established. Studies of other formulations or routes cannot establish an outcome for this product.

Risks

GHK-Cu Injection risks and side effects.

  • The safety of injected GHK-Cu in people has not been established. Side effects, interactions and longer-term risks are not adequately characterized.
  • Injection can cause pain, redness, swelling or bruising, and carries an infection risk if the product or injection technique is not sterile.
  • People with Wilson's disease, another disorder of copper metabolism or a known copper allergy require specific medical review before considering a copper-containing product.
  • Safety data are insufficient during pregnancy or breastfeeding. These groups should not use this product.
  • Seek urgent medical care for trouble breathing, swelling of the face or throat, or other signs of a serious allergic reaction.

This information is educational and is not medical advice. It does not establish a provider–patient relationship.

Clinical review

What your prescriber will consider.

These are decision factors a licensed provider weighs when deciding whether this product is appropriate for you. They are not instructions, and there is no dosing protocol on this page.

  • The lack of established human safety information for this injected formulation

  • Copper allergy or sensitivity, and any disorder affecting copper metabolism

  • Every medicine, supplement and other peptide product in use

  • Pregnancy, breastfeeding or plans to conceive

PEPLUX does not publish self-administration protocols. Dose, frequency and duration are set by your prescriber against your own history and reviewed over time.

Lot documents

What a certificate of analysis should cover.

When a pharmacy is named, each lot's certificate of analysis is expected to cover the tests below. No certificate exists or is published yet.

  • Potency
  • Sterility
  • Endotoxin
  • pH

Sport and anti-doping

WADA status.

  • Not named on the WADA 2026 Prohibited List.

The list is revised every year. If you compete, check the current list and your federation’s own rules.

Straight answers

Common questions about GHK-Cu Injection.

What is the FDA status of GHK-Cu Injection?
No compounding pathway today. GHK-Cu for non-injectable use, such as topical, is in FDA's 503A Category 1. FDA is still evaluating it and has said it does not intend to take action against a 503A pharmacy that compounds it against a patient-specific prescription while the interim policy's conditions are met. That is enforcement discretion, not a listing, and it has already been withdrawn once. Injectable GHK-Cu has no compounding pathway. Compounded GHK-Cu is not FDA-approved. FDA does not check the safety, effectiveness or quality of compounded drugs before they are sold. Checked against primary sources on October 13, 2026.
Is compounded GHK-Cu Injection an approved drug?
No. Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality. GHK-Cu Injection is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established. PEPLUX is a telehealth platform, not a pharmacy or drug manufacturer. Medications are compounded and dispensed by independently licensed US compounding pharmacies.
What does the evidence support for GHK-Cu Injection, and what does it not?
Human data for injected GHK-Cu are minimal, and its safety and effectiveness by injection have not been established. Studies of other formulations or routes cannot establish an outcome for this product.
What are the risks of GHK-Cu Injection?
The safety of injected GHK-Cu in people has not been established. Side effects, interactions and longer-term risks are not adequately characterized. The full list of side effects, and of who should not use GHK-Cu Injection, is in the risks section of this page. Your prescriber reviews your history before deciding whether it is appropriate for you.
Does GHK-Cu Injection require baseline labs?
No. GHK-Cu Injection does not require baseline labs, though your prescriber may order them based on your history. Baseline labs are included in the price.
What does GHK-Cu Injection cost?
$229 per month. Medication: included. Clinician visit: included. Baseline labs: included. Lab retests: included when ordered by your provider. Shipping: included. Patient portal access: included. Care-team chat support: included. *If medically eligible.
Is GHK-Cu Injection prohibited in sport?
Not named on the WADA 2026 Prohibited List.
How is GHK-Cu Injection given?
Subcutaneous injection. Your prescriber decides whether it is appropriate for you and sets the regimen. PEPLUX does not publish dosing.

Next step

A licensed provider reviews every request.

GHK-Cu Injection is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

Order now

No compounding pathway today.

*If medically eligible.

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

Also offered

Other products.

All productsFDA status tracker